Lung Ultrasound for Assessment of Interstitial Lung Disease in Systemic Sclerosis: Relationship With High-Resolution Computed Tomography and Nailfold Capillaroscopy

肺部超声在系统性硬化症间质性肺疾病评估中的应用:与高分辨率计算机断层扫描和甲襞毛细血管镜检查的关系

阅读:1

Abstract

BACKGROUND: Lung ultrasound (LUS) has been recently proposed as a convenient and radiation-free imaging modality for the evaluation of systemic sclerosis-related interstitial lung disease. OBJECTIVES: The current study evaluates the relation between LUS and both high-resolution computed tomography (HRCT) and capillaroscopy findings in patients with systemic sclerosis. DESIGN: This cross-sectional study included 32 patients with systemic sclerosis. METHODS: Besides clinical evaluation, all participants underwent LUS, HRCT, pulmonary function tests (PFT), and nailfold video-capillaroscopy (NVC). All participants' data were compared and correlated. RESULTS: There is an excellent agreement between number of B-lines and HRCT score (interclass correlation = 0.864, P-value < .001). A significant positive correlation exists between number of B-lines and disease duration (r = 0.459, P-value = .008). Conversely, the number of B-lines is negatively correlated with capillary density (r = -0.687, P-value < .001), forced expiratory volume in the first second (FEV1) (r = -0.886, P-value < .001), and forced vital capacity (FVC) (r = -0.898, P-value < .001). Patients with either neoangiogenesis or previous/current digital ulcers had significantly higher number of B-lines than those without (P-value < .001, .016, respectively). CONCLUSION: The number of B-lines parallels the HRCT score and the extent of digital vascular damage as indicated by NVC and clinical digital ulcers. Lung ultrasound has proven to be a reliable radiation-free modality for screening of systemic sclerosis-related interstitial lung disease and detecting its extent.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。